Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia - 1 Sept 2021

Mihaila Romeo Gabriel, Topircean Diana

Abstract excerpt

Knowledge on acute myeloid leukemia pathogenesis and treatment has progressed recently, but not enough to provide ideal management. Improving the prognosis of acute myeloid leukemia patients depends on advances in molecular biology for the detection of new therapeutic targets and the production of effective drugs. The CRISPR/Cas9 technology allows gene insertions and deletions and it is the first step in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Technology

Source

Identifiers

PMID: 34446939
DOI: 10.5507/bp.2021.048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia.PMID 34446939Read ↗

CRISPR-Cas9 in basic and translational aspects of cancer therapySemantic proximity Read ↗

Identification of novel genetic vulnerabilities and therapeutic targets in acute myeloid leukaemia using CRISPR dropout screensSemantic proximity Read ↗

Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implicationsSemantic proximity Read ↗

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

High-Throughput CRISPR Screening in Hematological NeoplasmsSemantic proximity Read ↗

High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cellsSemantic proximity Read ↗

From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques.Semantic proximity Read ↗

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemiaSemantic proximity Read ↗

Characterizing genes associated with cancer using the CRISPR/Cas9 system: A systematic review of genes and methodological approaches.Semantic proximity Read ↗

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapySemantic proximity Read ↗

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatmentSemantic proximity Read ↗

Alternative strategy to induce CRISPR-mediated genetic changes in hematopoietic cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.